HealthcareServices

Global Spinal Muscular Atrophy Industry Insights: Key Trends and Growth Estimates

March 3, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the spinal muscular atrophy market from 2026–2035 with trusted insights from The Business Research Company

Across 2026–2030, what is the expected market valuation path of the Spinal Muscular Atrophy Market?

The market for spinal muscular atrophy has experienced swift expansion recently. Projections indicate its value will escalate from $4 billion in 2025 to $4.53 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 13.2%. Historically, this expansion has been driven by the introduction of innovative SMA therapies, a rise in genetic testing, heightened awareness from advocacy groups, significant investments in clinical trials, and dedicated funding for rare diseases.

The spinal muscular atrophy market is expected to witness substantial expansion in the upcoming years, projected to achieve a value of $7.34 billion by 2030, advancing at a compound annual growth rate (CAGR) of 12.9%. This predicted rise is attributed to innovations in next-generation gene therapies, widespread adoption of global screening, broader availability of treatment options, improved patient survival, and ongoing pipeline drug development. Significant trends anticipated during this period include earlier genetic diagnosis, the proliferation of disease-modifying therapies, the introduction of newborn screening initiatives, tailored treatment approaches, and comprehensive long-term disease management strategies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20965&type=smp

Which Drivers Are Supporting The Rise Of The Spinal Muscular Atrophy Market?

The anticipated increase in the occurrence of rare genetic diseases is set to boost the expansion of the spinal muscular atrophy market in the future. These disorders stem from gene mutations, impacting a small portion of people and frequently leading to serious, long-term health issues. This growing prevalence is linked to advancements in diagnostic methods, greater public understanding, and enhanced availability of genetic testing, all contributing to the detection and reporting of more cases. Spinal muscular atrophy (SMA) serves as a prime example of a rare genetic disorder, illustrating both the difficulties and possibilities in comprehending inherited illnesses and underscoring the necessity of progressing research into genetic conditions. To illustrate, a report from the UK’s Office for National Statistics in July 2023 indicated that specific epidemiological studies, made possible by SMN1 genetic testing, showed SMA affects 1 of 10,000 to 20,000 live births, with more than 95% of patients having homozygous SMN1 deletion. Consequently, the increasing occurrence of rare genetic diseases is projected to fuel the expansion of the spinal muscular atrophy market.

What Leading Segments Are Studied In The Spinal Muscular Atrophy Market?

The spinal muscular atrophy market covered in this report is segmented –

1) By Type: Type 1 (Severe), Type 2 (Intermediate), Type 3 (Mild), Type 4 (Adult)

2) By Age: Pediatric, Adults

3) By Treatment: Drug Therapy, Gene Therapy

4) By End User: Hospital pharmacy, Online pharmacy, Retail pharmacy

Subsegments:

1) By Type 1 (Severe): Infantile-Onset SMA, Severe Progressive SMA

2) By Type 2 (Intermediate): Early-Onset SMA, Non-progressive SMA

3) By Type 3 (Mild): Juvenile-Onset SMA, Mild Progressive SMA

4) By Type 4 (Adult): Adult-Onset SMA, Late-Onset SMA

What Industry Trends Are Transforming The Spinal Muscular Atrophy Market?

Leading companies in the spinal muscular atrophy market are actively developing innovative products, such as dry syrup, to enhance medication adherence and simplify administration for pediatric and other patient groups facing swallowing difficulties. Dry syrup is a powdered medication that requires reconstitution with water before use, commonly prescribed for children and patients who struggle to swallow tablets or capsules. For instance, in September 2024, Chugai Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, announced the receipt of regulatory approval from Japan’s Ministry of Health, Labour and Welfare for an expanded indication of its drug Evrysdi (risdiplam). This approval allows its application in pre-symptomatic spinal muscular atrophy (SMA) and extends dosing to infants under two months old. This development is vital as it enables the start of treatment before symptoms emerge, potentially improving therapeutic outcomes for affected infants. The decision was substantiated by data from the RAINBOWFISH study, which assessed Evrysdi’s safety and efficacy in infants diagnosed with SMA but not yet symptomatic. Results indicated that treated infants achieved key developmental milestones, such as unsupported sitting and enhanced motor skills, by 12 months, thereby emphasizing the drug’s potential to significantly alter the disease’s progression when administered at an early stage.

Which Major Industry Participants Are Leading The Spinal Muscular Atrophy Market Growth?

Major companies operating in the spinal muscular atrophy market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Bayer AG, Novartis AG, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Genentech Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., RegenXBio Inc., Cytokinetics Inc., AveXis Inc., Scholar Rock Inc., Genethon, CANbridge Pharmaceuticals Inc., NMD Pharma A/S, Hanugen Therapeutics Inc., Beijing Jinlan Gene Technology Co. Ltd, Sarepta Therapeutics, Amicus Therapeutics, Audentes Therapeutics, Solid Biosciences

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Spinal Muscular Atrophy Market?

North America was the largest region in the spinal muscular atrophy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Spinal Muscular Atrophy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20965&type=smp

Browse Through More Reports Similar to the Global Spinal Muscular Atrophy Market 2026, By The Business Research Company

Duchenne Muscular Dystrophy Dmd Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/duchenne-muscular-dystrophy-dmd-therapeutics-global-market-report

Spine Biologics Market Report 2026

https://www.thebusinessresearchcompany.com/report/spine-biologics-global-market-report

Muscle Wasting Disorders Market Report 2026

https://www.thebusinessresearchcompany.com/report/muscle-wasting-disorders-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795